Natco Pharma on Friday said the Supreme Court has dismissed Swiss pharma major Roche’s petition challenging a Delhi High Court order permitting the Hyderabad-based company to launch a generic version of Roche’s spinal muscular atrophy (SMA) drug Risdiplam.
The apex court took note of the concurrent findings of the single judge as well as the Division Bench of the Delhi High Court in denying injunctions against Natco Pharma, it said in a release.
“Having the benefit of the two successive orders, the Supreme Court was not convinced about the maintainability of the challenge by Roche and, therefore, dismissed the petition. This marks the final challenge Roche could have posed at the interim stage in the suit, which shall now proceed for trial in accordance with the law,” Natco Pharma said.
On October 9, following the Commercial Appellate Division of the Delhi High Court dismissing an appeal filed by the Swiss pharma company F. Hoffmann-La Roche AG against the single judge’s order, Natco Pharma said it has decided to launch a generic version of the drug with immediate effect at a MRP of ₹15,900.
Senior Advocate J. Sai Deepak appeared for Natco before the single judge and Division Bench of the Delhi High Court and was assisted by counsels on record S. Majumdar and Co. In the Supreme Court, Natco was represented by senior advocates Kapil Sibal, Gopal Subramanium and J. Sai Deepak.
Published – October 17, 2025 09:06 pm IST
